Diurnal intraocular pressure reduction with latanoprost 0.005% compared to timolol maleate 0.5% as monotherapy in subjects with exfoliation glaucoma.

Abstract

AIMS:

To compare the diurnal intraocular pressure (IOP) efficacy and safety of timolol vs latanoprost in subjects with exfoliation glaucoma (XFG).

METHODS:

A 3-month prospective, single-masked, active-controlled, parallel comparison performed in six centres in Greece that randomized subjects in a 1 : 1 ratio to either latanoprost in the evening (2000 hours) and placebo in the morning (0800 hours), or timolol twice daily (0800 and 2000 hours).

RESULTS:

In all, 103 subjects completed the study. After 3 months of chronic dosing, the latanoprost group exhibited a trend to a greater diurnal IOP reduction from an untreated baseline (24.9+/-3.2-17.4+/-2.9) compared with timolol (24.7+/-2.8-18.3+/-1.9 mmHg) (P=0.07). Latanoprost showed a significantly greater IOP reduction at 0800 hours (-8.5 vs -6.0 mm Hg for timolol, P<0.0001) whereas no difference was observed between the two medications at 1000, 1400, and 2000 hours after a Bonferroni Correction. In addition, latanoprost demonstrated a narrower range of diurnal IOP (2.4) than timolol (3.2 mmHg)(P=0.0017). Safety was similar between groups, except there was more conjunctival hyperaemia with latanoprost (n=8) than timolol (n=1)(P=0.01).

CONCLUSIONS:

This study suggests that latanoprost provides a statistically lower 08:00-hour IOP and better range of IOP than timolol in the treatment of XFG glaucoma.

• Authors: A G P Konstas, N Mylopoulos, C H Karabatsas, V P Kozobolis, S Diafas, P Papapanos, N Georgiadis, W C Stewart
• Journal: Eye (London, England) (Eye (Lond)) Vol. 18 Issue 9 Pg. 893-9 (Sep 2004) ISSN: 0950-222X [Print] England
• PMID: 15002024 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Antihypertensive Agents
• Prostaglandins F, Synthetic
• Latanoprost
• Timolol

Topics

• Adult
• Aged
• Antihypertensive Agents (adverse effects, therapeutic use)
• Circadian Rhythm (drug effects)
• Exfoliation Syndrome (drug therapy, physiopathology)
• Female
• Glaucoma, Open-Angle (drug therapy, physiopathology)
• Humans
• Intraocular Pressure (drug effects)
• Latanoprost
• Male
• Middle Aged
• Prospective Studies
• Prostaglandins F, Synthetic (adverse effects, therapeutic use)
• Single-Blind Method
• Timolol (adverse effects, therapeutic use)